Who is sponsoring NCT06987617?

NCT06987617 is sponsored by Endo Health GmbH.

What drugs are being tested in NCT06987617?

Interventions in NCT06987617: Menopause App.

What condition does NCT06987617 study?

NCT06987617 studies Menopausal and Other Perimenopausal Disorders.

Is NCT06987617 still recruiting?

NCT06987617 is currently completed. Last updated 23 May 2025.

Last reviewed 2025-05-23 · How we verify

NCT06987617

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study to Investigate the Impact of an App on the Quality of Life and Symptoms of Individuals Affected by Menopause

Completed NA Last updated 23 May 2025

What this trial tests

NA trial testing Menopause App in Menopausal and Other Perimenopausal Disorders in 224 participants. Completed in 30 December 2024.

Timeline

9 August 2024

Primary endpoint
30 December 2024

30 December 2024

Quick facts

Lead sponsor	Endo Health GmbH
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	224
Start date	9 August 2024
Primary completion	30 December 2024
Estimated completion	30 December 2024
Sites	1 location across Germany

Drugs / interventions tested

Menopause App

Conditions studied

Menopausal and Other Perimenopausal Disorders — all drugs for Menopausal and Other Perimenopausal Disorders →

Sponsor

Endo Health GmbH

Who can join

18 and older, female only, with Menopausal and Other Perimenopausal Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study explores the impact of a digital app for the self-management of (peri-)menopausal disorders. A total of 224 participants were randomized into an intervention and a control group. Findings indicate that the app offers beneficial effects on menopausal symptoms and menopause-specific quality-of-life. The study also provided valuable insights for the design of future larger trials and highlights the promising potential of the app to enhance individualized care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Endo Health GmbH trials

Trials by the same sponsor.

NCT06991413 — Impact of an App on the Quality of Life and Symptoms in Individuals With Premenstrual Syndrome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06987617 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endo Health GmbH
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06987617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing